Breaking News Instant updates and real-time market news.

FTSV

Forty Seven

$35.98

-0.49 (-1.34%)

08:16
01/10/20
01/10
08:16
01/10/20
08:16

Forty Seven expects to initiate Phase 3 ENHANCE trial in 2020

Forty Seven is focused on advancing magrolimab in registration-enabling programs for the treatment of patients with untreated, higher-risk myelodysplastic syndrome and heavily-pretreated, relapsed or refractory diffuse large B-cell lymphoma. Magrolimab has previously been granted Fast Track designation by the FDA for the treatment of MDS and acute myeloid leukemia, and for the treatment of relapsed or refractory DLBCL and follicular lymphoma, as well as Orphan Drug designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of AML. In December 2019, the FDA granted Orphan Drug designation to magrolimab for the treatment of MDS. The company expects to achieve the following milestones in 2020: Myelodysplastic Syndrome: Initiate Phase 3 ENHANCE trial evaluating the combination of magrolimab and azacitidine compared to azacitidine alone in patients with untreated, higher risk-MDS in the second quarter; Present updated data from the ongoing Phase 1b clinical trial evaluating the combination of magrolimab and azacitidine in untreated patients with higher risk MDS mid-year; Complete enrollment in the ongoing Phase 1b clinical trial in the third quarter. Diffuse Large B-Cell Lymphoma: Initiate single-arm, registration-enabling trial evaluating the combination of magrolimab and rituximab in heavily pre-treated relapsed or refractory DLBCL patients who have failed at least two prior lines of therapy in the first quarter; Present initial data from the registration-enabling trial in the fourth quarter.

FTSV Forty Seven
$35.98

-0.49 (-1.34%)

12/10/19
MSCO
12/10/19
NO CHANGE
Target $45
MSCO
Overweight
Forty Seven price target raised to $45 from $17 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison said data presented by Forty Seven at the ASH meeting support the potential for magrolimab to be superior to azacitadine in myelodysplastic syndrome, or MDS, and potentially also acute myeloid leukemia, or AML. In addition, Harrison notes that Forty Seven management finalized a regulatory plan that provides two paths to accelerated approval. Given the new data and approval path details, Harrison lowered his discount rate and also increased his peak sales estimate for the MDS indication to about $800M from $600M, leading him to increase his price target on Forty Seven shares to $45 from $17. He maintains an Overweight rating on the stock.
12/10/19
ROTH
12/10/19
NO CHANGE
Target $35
ROTH
Buy
Forty Seven price target raised to $35 from $28 at Roth Capital
Roth Capital analyst Tony Butler raised his price target for Forty Seven to $35 from $28 after the company provided an update of data on the anti-CD47 mAb magrolimab in patients with high-risk MDS and AML at the ASH meeting. Of 46 evaluable patients, Butler says the overall response was 92% and 64%, respectively, and the complete response/complete response with incomplete hematological recovery was 50% in MDS, and 55% in AML. Butler maintains a Buy rating on the shares.
12/11/19
GUGG
12/11/19
NO CHANGE
Target $48
GUGG
Buy
Forty Seven price target to $48 from $20 at Guggenheim
Guggenheim analyst Etzer Darout raised his price target for Forty Seven to $48 from $20 following the company's updates at the American Society of Hematology conference. The analyst ere we came away "incrementally more positive" on the magrolimab and azacitidine combination in myelodysplastic syndromes patients and the response that the magrolimab combination has shown in acute myeloid leukemia patients. He reiterates a Buy rating on Forty Seven shares.
01/07/20
ROTH
01/07/20
NO CHANGE
Target $55
ROTH
Buy
Forty Seven price target raised to $55 from $35 at Roth Capital
Roth Capital analyst Tony Butler raised his price target for Forty Seven to $55 from $35 ahead of data from two early phase Ib trials evaluating magrolimab combinations with tumor-targeting antibodies in colorectal and ovarian cancers. The analyst reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

TER

Teradyne

$73.08

1.55 (2.17%)

15:34
01/22/20
01/22
15:34
01/22/20
15:34
Options
Teradyne options imply 10.2% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CTXS

Citrix

$119.45

1.66 (1.41%)

15:19
01/22/20
01/22
15:19
01/22/20
15:19
Options
Citrix options imply 7.2% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
01/22/20
01/22
15:17
01/22/20
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
01/22/20
01/22
15:16
01/22/20
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$72.03

-7.66 (-9.61%)

15:10
01/22/20
01/22
15:10
01/22/20
15:10
Recommendations
Blueprint Medicines analyst commentary  »

Amendment to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 23

    Jan

JBHT

J.B. Hunt

$114.20

-1.63 (-1.41%)

15:09
01/22/20
01/22
15:09
01/22/20
15:09
Hot Stocks
J.B. Hunt raises quarterly dividend to 27c from 26c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

TXN

Texas Instruments

$133.23

2.38 (1.82%)

15:04
01/22/20
01/22
15:04
01/22/20
15:04
Options
Texas Instruments options imply 7.4% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

QSR

Restaurant Brands

$65.41

0.085 (0.13%)

, TAST

Carrols Restaurant

$5.01

-0.1 (-1.96%)

14:55
01/22/20
01/22
14:55
01/22/20
14:55
Periodicals
Burger King cutting Impossible Whopper price as sales slow, Bloomberg says »

Burger King, a Restaurant…

QSR

Restaurant Brands

$65.41

0.085 (0.13%)

TAST

Carrols Restaurant

$5.01

-0.1 (-1.96%)

BYND

Beyond Meat

$124.60

-4.64 (-3.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPR

Express

$4.96

0.81 (19.52%)

14:51
01/22/20
01/22
14:51
01/22/20
14:51
Recommendations
Express analyst commentary  »

Wedbush…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

BYND

Beyond Meat

$125.41

-3.83 (-2.96%)

, QSR

Restaurant Brands

$65.43

0.105 (0.16%)

14:51
01/22/20
01/22
14:51
01/22/20
14:51
Periodicals
Burger King cutting Impossible Whopper price as sales slow, Bloomberg says »

Shares of Beyond Meat,…

BYND

Beyond Meat

$125.41

-3.83 (-2.96%)

QSR

Restaurant Brands

$65.43

0.105 (0.16%)

TAST

Carrols Restaurant

$5.02

-0.09 (-1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMI

Kinder Morgan

$21.04

0.11 (0.53%)

14:49
01/22/20
01/22
14:49
01/22/20
14:49
Options
Kinder Morgan options imply 2.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

VZ

Verizon

$60.68

0.36 (0.60%)

, GOOG

Alphabet

$1,493.50

8.58 (0.58%)

14:43
01/22/20
01/22
14:43
01/22/20
14:43
Hot Stocks
Verizon partners with Google Stadia for cloud gaming »

"It's no…

VZ

Verizon

$60.68

0.36 (0.60%)

GOOG

Alphabet

$1,493.50

8.58 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 03

    Feb

MDC

M.D.C. Holdings

$43.74

0.51 (1.18%)

14:39
01/22/20
01/22
14:39
01/22/20
14:39
Hot Stocks
Richmond American Homes plans to acquire 1,000 sites at Aurora Highlands »

Richmond American Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

CHCO

City Holding

$80.65

0.14 (0.17%)

14:32
01/22/20
01/22
14:32
01/22/20
14:32
Hot Stocks
City Holding announces pre-tax gain of $17.8M on sale of Visa Class B shares »

City Holding Company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$66.49

0.19 (0.29%)

14:31
01/22/20
01/22
14:31
01/22/20
14:31
Hot Stocks
Comerica names Melinda Chausse chief credit officer »

Comerica announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Feb

AAOI

Applied Optoelectronics

$14.23

0.51 (3.72%)

14:25
01/22/20
01/22
14:25
01/22/20
14:25
Options
Applied Optoelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$126.65

0.54 (0.43%)

, UNP

Union Pacific

$181.23

-1.27 (-0.70%)

14:22
01/22/20
01/22
14:22
01/22/20
14:22
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$126.65

0.54 (0.43%)

UNP

Union Pacific

$181.23

-1.27 (-0.70%)

KMB

Kimberly-Clark

$145.50

0.91 (0.63%)

VFC

VF Corp.

$95.12

0.49 (0.52%)

LUV

Southwest

$53.64

0.1 (0.19%)

MTB

M&T Bank

$162.54

1.655 (1.03%)

KEY

KeyCorp

$19.61

0.11 (0.56%)

HBAN

Huntington Bancshares

$14.84

0.22 (1.51%)

AAL

American Airlines

$27.50

0.29 (1.07%)

JBLU

JetBlue

$19.90

0.81 (4.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 17

    Feb

  • 04

    Mar

TXN

Texas Instruments

$133.66

2.81 (2.15%)

, KMI

Kinder Morgan

$21.05

0.12 (0.57%)

14:22
01/22/20
01/22
14:22
01/22/20
14:22
Earnings
Notable companies reporting after market close »

Notable companies…

TXN

Texas Instruments

$133.66

2.81 (2.15%)

KMI

Kinder Morgan

$21.05

0.12 (0.57%)

CTXS

Citrix

$119.46

1.67 (1.42%)

TER

Teradyne

$73.17

1.64 (2.29%)

PTC

PTC

$79.86

0.93 (1.18%)

STLD

Steel Dynamics

$32.05

0.14 (0.44%)

SLM

Sallie Mae

$9.15

0.31 (3.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 29

    Jan

  • 12

    Feb

  • 26

    Feb

XOM

Exxon Mobil

$67.01

-0.58 (-0.86%)

14:17
01/22/20
01/22
14:17
01/22/20
14:17
Periodicals
Exxon Mobil set to kick off U.K., Germany asset sales, Bloomberg says »

Exxon Mobil intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

CHEOY

Cochlear

$0.00

(0.00%)

14:17
01/22/20
01/22
14:17
01/22/20
14:17
Downgrade
Cochlear rating change  »

Cochlear downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
01/22/20
01/22
14:17
01/22/20
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
01/22/20
01/22
14:16
01/22/20
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPG

Simon Property

$146.15

-2.96 (-1.99%)

14:15
01/22/20
01/22
14:15
01/22/20
14:15
Options
Simon Property put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

FCEL

FuelCell

$2.15

-0.725 (-25.26%)

, PKX

Posco

$51.39

-0.15 (-0.29%)

14:14
01/22/20
01/22
14:14
01/22/20
14:14
On The Fly
FuelCell plunges on bigger than expected loss, revenue miss »

Shares of FuelCell (FCEL)…

FCEL

FuelCell

$2.15

-0.725 (-25.26%)

PKX

Posco

$51.39

-0.15 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 31

    Jan

NK

NantKwest

$5.94

-0.32 (-5.11%)

14:14
01/22/20
01/22
14:14
01/22/20
14:14
Hot Stocks
Breaking Hot Stocks news story on NantKwest 

NantKwest trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.